Table 4 Incidence rates of infusion/injection reactions by bDMARD treatment
Outcomes | Abatacept | Other bDMARDs | ||||||
|---|---|---|---|---|---|---|---|---|
Overall | TNFi | Non-TNFi bDMARDs | ||||||
No. of events/ no. of patients | IR (95% CI)* | No. of events/ no. of patients | IR (95% CI)* | No. of events/ no. of patients | IR (95% CI)* | No. of events/ no. of patients | IR (95% CI)* | |
Any infusion reaction | 115/1330 | 5.36 (4.42, 6.43) | 196/1336 | 9.25 (8.00, 10.64) | 106/985 | 7.00 (5.73, 8.47) | 74/501 | 9.38 (7.36, 11.77) |
Severe infusion reactions | 27/1330 | 1.26 (0.83, 1.83) | 41/1336 | 1.94 (1.39, 2.63) | 24/985 | 1.59 (1.02, 2.36) | 12/501 | 1.52 (0.79, 2.66) |
Any injection reaction | 53/626 | 8.19 (6.13, 10.71) | 573/1690 | 23.43 (21.55, 25.43) | 550/1679 | 22.62 (20.76, 24.59) | 3/20 | 12.46 (2.57, 36.41) |
Severe injection reactions | 3/626 | 0.46 (0.10, 1.35) | 46/1690 | 1.88 (1.38, 2.51) | 40/1679 | 1.65 (1.18, 2.24) | 1/20 | 4.15 (0.11, 23.14) |
Severe injection or infusion reactions | 37/1496 | 1.57 (1.11, 2.17) | 95/2648 | 2.31 (1.87, 2.82) | 65/2361 | 1.85 (1.42, 2.35) | 14/512 | 1.75 (0.95, 2.93) |